In this report, according to this study, over the next five years the Oncology Anti-Cancer Drugsmarket will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026, from US$ xx million in 2020. In particular, this report presents the global market share (sales and revenue) of key companies in Oncology Anti-Cancer Drugsbusiness.
Oncology Anti-Cancer Drugs market development trend, sales volume and sales value (million USD) forecast in regional market, the main regions are China, USA, Europe, India, Japan, Korea, South America, Southeast Asia.
Sales forecast by type/application from 2021-2026
Industry chain, downstream and upstream information is also included.
Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Oncology Anti-Cancer Drugs for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
Global Oncology Anti-Cancer Drugs market competition by top manufacturers/players, with Oncology Anti-Cancer Drugs sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
Amgen
AstraZeneca
Roche Diagnostics
GlaxoSmithKline
Merck
Novartis
AbbVie
Sanofi
EIMC United Pharmaceuticals
Actavis
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Oncology Anti-Cancer Drugs for each application, including
Blood Cancer (Leukaemia)
Breast Cancer
Gastrointestinal Cancer
Respiratory/Lung Cancer
Skin Cancer
Other Cancers
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
1 Executive Summary
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Oncology Anti-Cancer Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Analysis by Types
2.1 Overall Market Performance(Volume)
2.1.1 Chemotherapy
2.1.2 Targeted Therapy
2.1.3 Immunotherapy (Biologic Therapy)
2.1.4 Hormonal Therapy
2.1.5 Others
2.2 Overall Market Performance(Value)
2.2.1 Chemotherapy
2.2.2 Targeted Therapy
2.2.3 Immunotherapy (Biologic Therapy)
2.2.4 Hormonal Therapy
2.2.5 Others
3 Product Application Market
3.1 Overall Market Performance (Volume)
3.1.1 Blood Cancer (Leukaemia)
3.1.2 Breast Cancer
3.1.3 Gastrointestinal Cancer
3.1.4 Respiratory/Lung Cancer
3.1.5 Skin Cancer
3.1.6 Other Cancers
4 Manufacturers Profiles/Analysis
4.1 Amgen
4.1.1 Amgen Profiles
4.1.2 Amgen Product Information
4.1.3 Amgen Oncology Anti-Cancer Drugs Sales, Sales Value(Million USD), Price and Gross Profit
4.1.4 Amgen SWOT Analysis
4.2 AstraZeneca
4.2.1 AstraZeneca Profiles
4.2.2 AstraZeneca Product Information
4.2.3 AstraZeneca Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.2.4 AstraZeneca SWOT Analysis
4.3 Roche Diagnostics
4.3.1 Roche Diagnostics Profiles
4.3.2 Roche Diagnostics Product Information
4.3.3 Roche Diagnostics Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.3.4 Roche Diagnostics SWOT Analysis
4.4 GlaxoSmithKline
4.4.1 GlaxoSmithKline Profiles
4.4.2 GlaxoSmithKline Product Information
4.4.3 GlaxoSmithKline Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.4.4 GlaxoSmithKline SWOT Analysis
4.5 Merck
4.5.1 Merck Profiles
4.5.2 Merck Product Information
4.5.3 Merck Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.5.4 Merck SWOT Analysis
4.6 Novartis
4.6.1 Novartis Profiles
4.6.2 Novartis Product Information
4.6.3 Novartis Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.6.4 Novartis SWOT Analysis
4.7 AbbVie
4.7.1 AbbVie Profiles
4.7.2 AbbVie Product Information
4.7.3 AbbVie Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.7.4 AbbVie SWOT Analysis
4.8 Sanofi
4.8.1 Sanofi Profiles
4.8.2 Sanofi Product Information
4.8.3 Sanofi Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.8.4 Sanofi SWOT Analysis
4.9 EIMC United Pharmaceuticals
4.9.1 EIMC United Pharmaceuticals Profiles
4.9.2 EIMC United Pharmaceuticals Product Information
4.9.3 EIMC United Pharmaceuticals Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.9.4 EIMC United Pharmaceuticals SWOT Analysis
4.10 Actavis
4.10.1 Actavis Profiles
4.10.2 Actavis Product Information
4.10.3 Actavis Oncology Anti-Cancer DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.10.4 Actavis SWOT Analysis
5 Market Performance for Manufacturers
5.1 Global Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
5.2 Global Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
5.3 Global Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
5.4 Global Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
5.5 Market Concentration
6 Regions Market Performance for Manufacturers
6.1 China Market Performance for Manufacturers
6.1.1 China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.1.2 China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.1.3 China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.1.4 China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.1.5 Market Concentration
6.2 USA Market Performance for Manufacturers
6.2.1 USA Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.2.2 USA Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.2.3 USA Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.2.4 USA Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.2.5 Market Concentration
6.3 Europe Market Performance for Manufacturers
6.3.1 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.3.2 Europe Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.3.3 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.3.4 Europe Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.3.5 Market Concentration
6.4 Japan Market Performance for Manufacturers
6.4.1 Japan Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.4.2 Japan Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.4.3 Japan Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.4.4 Japan Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.4.5 Market Concentration
6.5 Korea Market Performance for Manufacturers
6.5.1 Korea Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.5.2 Korea Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.5.3 Korea Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.5.4 Korea Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.5.5 Market Concentration
6.6 India Market Performance for Manufacturers
6.6.1 India Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.6.2 India Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.6.3 India Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.6.4 India Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.6.5 Market Concentration
6.7 Southeast Asia Market Performance for Manufacturers
6.7.1 Southeast Asia Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.7.2 Southeast Asia Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.7.3 Southeast Asia Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.7.4 Southeast Asia Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.7.5 Market Concentration
6.8 South America Market Performance for Manufacturers
6.8.1 South America Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.8.2 South America Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.8.3 South America Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.8.4 South America Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.8.5 Market Concentration
7 Global Oncology Anti-Cancer Drugs Market Assessment by Regions (2014-2020)
7.1 Global Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Regions 2014-2020
7.2 Global Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Regions 2014-2020
7.3 Global Oncology Anti-Cancer Drugs Price (USD/Unit) by Regions 2014-2020
7.4 Global Oncology Anti-Cancer Drugs Gross Margin by Regions 2014-2020
8 Development Trend for Regions
8.1 Global Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.2 China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.3 USA Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.4 Europe Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.5 Japan Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.6 Korea Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.7 India Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.8 Southeast Asia Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.8 Southeast Asia Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
9 Upstream Source, Technology and Cost
9.1 Upstream Source
9.2 Technology
9.3 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Manufacturing Plants Distribution
11 Consumer Analysis
11.1 Blood Cancer (Leukaemia) Industry
11.2 Breast Cancer Industry
11.3 Gastrointestinal Cancer Industry
11.4 Respiratory/Lung Cancer Industry
11.5 Skin Cancer Industry
11.6 Other Cancers Industry
12 Market Forecast 2021-2026
12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
12.1.1 Global Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
12.1.2 Global Oncology Anti-Cancer Drugs Sales (K Units) and Growth Rate 2021-2026
12.1.3 China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.4 USA Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.5 Europe Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.6 Japan Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.7 Korea Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.8 India Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.9 Southeast Asia Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.10 South America Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2021-2026
12.2.1 Overall Market Performance
12.2.2 Chemotherapy
12.2.3 Targeted Therapy
12.2.4 Immunotherapy (Biologic Therapy)
12.2.5 Hormonal Therapy
12.2.6 Others
12.3 Sales (K Units) Forecast by Application 2021-2026
12.3.1 Overall Market Performance
12.3.2 Blood Cancer (Leukaemia)
12.3.3 Breast Cancer
12.3.4 Gastrointestinal Cancer
12.3.5 Respiratory/Lung Cancer
12.3.6 Skin Cancer
12.3.7 Other Cancers
12.4 Price (USD/Unit) and Gross Profit
12.4.1 Global Oncology Anti-Cancer Drugs Price (USD/Unit) Trend 2021-2026
12.4.2 Global Oncology Anti-Cancer Drugs Gross Profit Trend 2021-2026
13 Conclusion
Price : US$ 3500 |
Date : Mar 2024 |
Category : Services |
Pages : 123 |